Evidence map›Paper›PMID 41264092›Full record

Observational studyClinical pharmacokinetics2026

Population Pharmacokinetics of Propofol in Critically Ill Patients with and Without Extracorporeal Membrane Oxygenation.

Stéphane Bertin, David Haefliger, Thomas Mercier, Laurent A Decosterd, Raphaël Giraud, Benjamin Assouline, Antoine Schneider, Thierry Buclin, Monia Guidi, Françoise Livio

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stéphane BertinService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
David HaefligerService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Thomas MercierLaboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Laurent A DecosterdLaboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Raphaël GiraudService of Intensive Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Benjamin AssoulineService of Intensive Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Antoine SchneiderAdult Intensive Care Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Thierry BuclinService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Monia Guidi *Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Françoise Livio *Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. francoise.livio@chuv.ch.ORCID 0000-0001-7427-5953

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivePropofol is commonly used in critically ill patients on extracorporeal membrane oxygenation (ECMO). Although ECMO may theoretically affect drug pharmacokinetics (PK) through various mechanisms, data on propofol PK in this context remain scarce, with only one small recent study available. Our aim was to assess the impact of ECMO on propofol PK in a larger cohort.

methodsWe conducted a prospective, bicentric observational PK study in critically ill patients with and without ECMO (controls). Critically ill adults receiving a continuous infusion of propofol were eligible for inclusion. Controls were selected to ensure similarity with ECMO patients. We collected a maximum of eight samples per patient over 9 h. We analysed plasma samples using a high-performance liquid chromatography coupled to tandem mass spectrometry validated method. We developed a population pharmacokinetic (popPK) model using a classical stepwise approach with nonlinear mixed effects modelling software.

resultsA total of 40 patients, 20 with and 20 without ECMO, contributed 300 samples. A two-compartment model best described the data, with body weight affecting clearance. ECMO had no substantial impact on propofol PK. The final popPK model parameter estimates with between-subject variability were as follows: clearance 68 L/h (34%), intercompartmental clearance 26 L/h, and central and peripheral volumes of distribution 1.2 L/kg (230%) and 1.4 L/kg, respectively. A proportional error model best described the residual unexplained variability (13%).

conclusionsOur popPK analysis shows that propofol PK does not differ between critically ill patients with and without ECMO and confirms a high PK variability in this population.

Indexed as

Anesthetics, IntravenousCritical IllnessExtracorporeal Membrane OxygenationPropofolAdultAgedFemaleHumansMaleMiddle AgedModels, BiologicalProspective StudiesAnesthetics, IntravenousPropofol

Identifiers

PMID41264092
PMCPMC12881008

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.